TY - JOUR
T1 - An analysis of monocytes and dendritic cells differentiated from human peripheral blood monocyte-derived induced pluripotent stem cells
AU - Hiramatsu, Noriko
AU - Yamamoto, Naoki
AU - Isogai, Sumito
AU - Onouchi, Takanori
AU - Hirayama, Masaya
AU - Maeda, Shingo
AU - Ina, Takuma
AU - Kondo, Masashi
AU - Imaizumi, Kazuyoshi
N1 - Funding Information:
We thank Hiromi Yamashita, Chieko Oka, and Naomi Maeda (Fujita Health University) for supporting the Experiments. This work was supported by MEXT/JSPS KAKENHI Grant Numbers JP17K09677, JP17K11495, and 18K15935.
Funding Information:
We thank Hiromi Yamashita, Chieko Oka, and Naomi Maeda (Fujita Health University) for supporting the Experiments. This work was supported by MEXT/JSPS KAKENHI Grant Numbers JP17K09677, JP17K11495, and 18K15935.
Publisher Copyright:
© 2019, The Japanese Society for Clinical Molecular Morphology.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.
AB - Dendritic cell-based immunotherapy, which uses a patient's own immune cells, can be used for cancer treatment and allergy control, such as autoimmune disease and rejection associated with transplantation. However, these treatments create a burden on patients due to repeated blood collection. We used cell biological analysis of monocytes with few mutations obtained from minimal blood collection for genome recombination. Next, we established human peripheral blood monocyte-derived induced pluripotent stem cells (iPSCs) using a commercial vector and standard culture method. We found that when established iPSCs were induced to differentiate, monocytes showed phagocytic properties and expressed CD14 and CX3CR1. Further, the generated dendritic cells (DCs) expressed CCL17 and highly expressed HLA-DR following the addition of the mite antigen. Taken together, these data show that monocyte-derived iPS cells can be used to differentiate into monocytes and DCs. In addition, the use of these cells can be applied to the pathological analysis of dendritic cell therapy and monocyte diseases.
UR - http://www.scopus.com/inward/record.url?scp=85074441607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074441607&partnerID=8YFLogxK
U2 - 10.1007/s00795-019-00231-8
DO - 10.1007/s00795-019-00231-8
M3 - Article
C2 - 31584115
AN - SCOPUS:85074441607
SN - 1860-1480
VL - 53
SP - 63
EP - 72
JO - Medical Molecular Morphology
JF - Medical Molecular Morphology
IS - 2
ER -